Patents by Inventor Michael Robert Turner

Michael Robert Turner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11358967
    Abstract: The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 14, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Delphine Collin, Johanna Csengery, Robert Owen Hughes, Michael Robert Turner, Lifen Wu
  • Publication number: 20220112189
    Abstract: The invention relates to compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of cryptosporidiosis by administering such a compound.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 14, 2022
    Inventors: Joseph Michael Young, Michael Robert Turner, Peichao Lu
  • Publication number: 20210171527
    Abstract: The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: January 18, 2017
    Publication date: June 10, 2021
    Inventors: Delphine COLLIN, Johanna CSENGERY, Robert Owen HUGHES, Michael Robert TURNER, Lifen WU
  • Publication number: 20210163449
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 3, 2021
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Publication number: 20210130302
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
    Type: Application
    Filed: September 24, 2020
    Publication date: May 6, 2021
    Inventors: Zef KONST, Yipin LU, Robert Joseph MOREAU, Naomi Samadara RAJAPAKSA, Galen SHEARN-NANCE, David Charles TULLY, Michael Robert TURNER, Joseph Michael YOUNG, Qian ZHAO, Britton K. CORKEY, Samuel E. METOBO
  • Patent number: 10889568
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 12, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Publication number: 20200399282
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: February 13, 2019
    Publication date: December 24, 2020
    Inventors: Steven Brunette, Jianwen Cui, Michael D. Lowe, Christopher Ronald Sarko, Simon Surprenant, Michael Robert Turner, Xinyuan Wu, Lana Louise Smith Keenan, Thierry Bouyssou, Paul Nicklin
  • Patent number: 10800757
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Patent number: 10624882
    Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: April 21, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, Jr., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young
  • Patent number: 10450314
    Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steven Richard Brunette, Johanna Csengery, Robert Owen Hughes, Xiang Li, Robert Sibley, Michael Robert Turner, Zhaoming Xiong
  • Publication number: 20190169167
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Publication number: 20190169168
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Publication number: 20190002465
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Johanna BAKONYI, Steven Richard BRUNETTE, Delphine COLLIN, Robert Owen HUGHES, Xiang LI, Shuang LIANG, Robert SIBLEY, Michael Robert TURNER, Lifen WU, Qiang ZHANG
  • Publication number: 20180344723
    Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
    Type: Application
    Filed: December 29, 2017
    Publication date: December 6, 2018
    Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, JR., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young
  • Publication number: 20180298005
    Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: September 28, 2016
    Publication date: October 18, 2018
    Inventors: Steven Richard BRUNETTE, Johanna CSENGERY, Robert Owen HUGHES, Xiang LI, Robert SIBLEY, Michael Robert TURNER, Zhaoming XIONG
  • Publication number: 20180022749
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: February 7, 2017
    Publication date: January 25, 2018
    Inventors: Johanna BAKONYI, Steven Richard BRUNETTE, Delphine COLLIN, Robert Owen HUGHES, Xiang LI, Shuang LIANG, Robert SIBLEY, Michael Robert TURNER, Lifen WU, Qiang ZHANG
  • Patent number: 9745297
    Abstract: The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: August 29, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, John D. Huber, Robert Owen Hughes, Xiang Li, Shuang Liang, Ingo Andreas Mugge, Michael Robert Turner, Qiang Zhang
  • Patent number: 9598415
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: March 21, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Johanna Bakonyi, Steven Richard Brunette, Delphine Collin, Robert Owen Hughes, Xiang Li, Shuang Liang, Robert Sibley, Michael Robert Turner, Lifen Wu, Qiang Zhang
  • Publication number: 20170008894
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: September 20, 2016
    Publication date: January 12, 2017
    Inventors: Johanna BAKONYI, Steven Richard BRUNETTE, Delphine COLLIN, Robert Owen HUGHES, Xiang LI, Shuang LIANG, Robert SIBLEY, Michael Robert TURNER, Lifen WU, Qiang ZHANG
  • Publication number: 20160243102
    Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
    Type: Application
    Filed: April 29, 2016
    Publication date: August 25, 2016
    Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, JR., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young